The applicability and safety of endoscopic ablation as a treatment for refractory GERD.(Anti-reflux mucosal ablation;ARMA)

The applicability and safety of endoscopic ablation as a treatment for refractory GERD.(Anti-reflux mucosal ablation;ARMA) - The efficacy and safety of endoscopic ablation in the management of refractory GERD.(Anti-reflux mucosal ablation;ARMA)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032190

Enrollment

Registered

2018-04-11

Start date

2018-04-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PPI refractory GERD

Interventions

Create post ablation scar endoscopically for fundoplication.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient with PPI refractory GERD.

Exclusion criteria

Exclusion criteria: Inability or unwillingness of patients to give written informed consent. Pregnancy. Judged unsuitable for this study by the physicians

Design outcomes

Primary

Measure	Time frame
The efficacy of Anti-reflux mucosal ablation for refractory GERD. f-scale and GERD-Q score 2 months, and 1 year after treatment.	—

Secondary

Measure	Time frame
Adverse event rate.	—

Countries

Japan

Contacts

Public ContactMayo Tanabe

Showa University Koto Toyosu Hospital Digestive Diseases Center

mayo.tanabe@gmail.com08039002330

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026